This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comReference country selection HHS provided guidance on setting benchmark pricing by considering the lowest price among a set of reference countries, defined by...
These substances may offer innovative treatment options for psychiatric conditions including PTSD, major and treatment-resistant depression, generalized...
CRA is a proud sponsor of the conference that aims to increase the prominence of women through professional development, substantive legal discussion, and...
Abhishek Kumar presents his poster titled “Top Trends Affecting the Vaccines Market and their Implications on Access Policy and Public Health...
